#1 Clinical Trials Search in Europe

Calcium Polystyrene Sulfonate

Calcium Polystyrene Sulfonate is a medication used in clinical trials to treat high potassium levels (hyperkalemia) and manage electrolyte imbalances, particularly in patients with kidney problems. This article explores its use, effectiveness, and comparison with other potassium-binding medications in various clinical settings.

Table of Contents

What is Calcium Polystyrene Sulfonate?

Calcium Polystyrene Sulfonate (CPS) is a medication used to treat high levels of potassium in the blood, a condition known as hyperkalemia. It belongs to a class of drugs called potassium binders or cation exchange resins. CPS is also known by other names, including:

  • Sodium Polystyrene Sulfonate (SPS)
  • Kayexalate
  • Solystat
These names may be used interchangeably in medical settings, but they all refer to similar medications that work in the same way[1][2].

Conditions Treated

Calcium Polystyrene Sulfonate is primarily used to treat hyperkalemia in patients with:

  • Chronic Kidney Disease (CKD): A long-term condition where the kidneys don’t function properly
  • Acute Kidney Injury (AKI): A sudden episode of kidney failure or kidney damage
  • Heart Failure: A condition where the heart can’t pump blood effectively
These conditions can often lead to high potassium levels in the blood, which can be dangerous if left untreated[3][4].

How It Works

Calcium Polystyrene Sulfonate works by binding to excess potassium in the intestines. When you take this medication, it travels through your digestive system and attracts potassium molecules. The medication then traps these potassium molecules and carries them out of your body through your stool. This process helps lower the amount of potassium in your blood[5].

Administration and Dosage

Calcium Polystyrene Sulfonate is typically administered orally as a powder mixed with water. The dosage can vary depending on the patient’s condition and potassium levels. Some common dosages seen in clinical trials include:

  • 15g mixed with 60 mL of water, taken once daily on non-dialysis days
  • 30g taken orally once daily for short periods (e.g., 7 days)
It’s important to note that the exact dosage should always be determined by a healthcare professional based on individual patient needs[2][1].

Effectiveness

Clinical trials have shown that Calcium Polystyrene Sulfonate can be effective in lowering potassium levels in patients with hyperkalemia. In one study, researchers found that CPS significantly reduced serum potassium levels compared to a placebo over a 48-hour period[5]. However, its effectiveness may vary from patient to patient, and it’s often used in combination with other treatments for managing hyperkalemia.

Side Effects and Considerations

While Calcium Polystyrene Sulfonate can be effective, it may cause some side effects. Common side effects reported in clinical trials include:

  • Gastrointestinal issues (nausea, constipation, diarrhea)
  • Electrolyte imbalances (changes in sodium, magnesium, or calcium levels)
  • Changes in blood pressure
It’s important to discuss any side effects with your healthcare provider. They may adjust your dosage or recommend alternative treatments if side effects become problematic[2][5].

Comparisons with Other Treatments

In recent years, new potassium binders have been developed, leading to comparisons between Calcium Polystyrene Sulfonate and newer medications. Some of these newer treatments include:

  • Sodium Zirconium Cyclosilicate (Lokelma)
  • Patiromer (Veltassa)
Clinical trials are ongoing to compare the effectiveness, safety, and patient preference between these different potassium binders. Some studies suggest that newer medications may have improved palatability and potentially fewer side effects, but more research is needed to confirm these findings[6][3].

Ongoing Research

Research on Calcium Polystyrene Sulfonate and other potassium binders is ongoing. Current studies are focusing on:

  • Comparing the effectiveness of different potassium binders in emergency settings
  • Evaluating patient preferences and palatability of various treatments
  • Assessing long-term safety and efficacy in different patient populations
These studies aim to provide more information to help healthcare providers make informed decisions about the best treatment options for patients with hyperkalemia[3][6].

Aspect Details
Primary Use Treatment of hyperkalemia, especially in patients with kidney problems
Mechanism of Action Exchanges calcium ions for potassium ions in the intestines
Administration Typically oral, as a powder mixed with water
Dosage in Trials Varies, often 15-30g daily or as needed
Comparison Studies Often compared to newer potassium binders like Lokelma and Veltassa
Efficacy Measures Change in serum potassium levels, proportion of patients achieving normokalemia
Safety Assessments Monitoring of adverse events, electrolyte imbalances
Patient Factors Palatability, preference, and adherence often evaluated
Clinical Settings Emergency rooms, outpatient clinics, pre-dialysis care
Research Focus Efficacy, safety, patient experience, comparison with other treatments

FAQ

  • What is Calcium Polystyrene Sulfonate used for in clinical trials? Calcium Polystyrene Sulfonate is primarily used in clinical trials to treat hyperkalemia (high potassium levels in the blood), especially in patients with chronic kidney disease or acute kidney injury.
  • How does Calcium Polystyrene Sulfonate work? It works as a potassium binder, exchanging calcium ions for potassium ions in the intestines, which helps remove excess potassium from the body through the stool.
  • Are there any side effects associated with Calcium Polystyrene Sulfonate? Common side effects may include nausea, constipation, diarrhea, and electrolyte imbalances. Some trials are specifically designed to assess the incidence of adverse events.
  • How is Calcium Polystyrene Sulfonate administered in clinical trials? It is typically administered orally, often as a powder mixed with water. The dosage and frequency can vary depending on the specific trial protocol and patient needs.
  • How does Calcium Polystyrene Sulfonate compare to other potassium binders in clinical trials? Some trials compare Calcium Polystyrene Sulfonate to newer potassium binders like Sodium Zirconium Cyclosilicate (Lokelma) and Patiromer (Veltassa) in terms of efficacy, palatability, and patient preference.

Ongoing Clinical Trials on Calcium Polystyrene Sulfonate

  • Study on Patiromer and Placebo for Managing Hyperkalemia in Non-Dialysis Patients with Chronic Kidney Disease Stages IIIB to V

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Hyperkalemia: A condition characterized by higher than normal levels of potassium in the blood, which can be dangerous and potentially life-threatening.
  • Chronic Kidney Disease (CKD): A long-term condition where the kidneys do not function properly, often leading to problems with electrolyte balance, including potassium levels.
  • Acute Kidney Injury (AKI): A sudden episode of kidney failure or kidney damage that happens within a few hours or days, which can cause rapid changes in electrolyte levels.
  • Electrolyte: Minerals in the blood and other bodily fluids that carry an electric charge and are essential for various bodily functions.
  • Potassium Binder: A medication designed to bind to excess potassium in the intestines, preventing its absorption and facilitating its removal from the body.
  • Serum Potassium: The level of potassium measured in the blood serum, used to diagnose and monitor hyperkalemia.
  • Normokalemia: Normal levels of potassium in the blood, typically between 3.5 to 5.0 mmol/L.
  • Palatability: How pleasant a substance is to taste, which can affect patient adherence to medication.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Randomized Clinical Trial: A study in which participants are randomly assigned to different treatment groups to compare the effectiveness of different interventions.

References

  1. https://clinicaltrials.gov/study/NCT02065076
  2. https://clinicaltrials.gov/study/NCT06029179
  3. https://clinicaltrials.gov/study/NCT04585542
  4. https://clinicaltrials.gov/study/NCT06218212
  5. https://clinicaltrials.gov/study/NCT01866709
  6. https://clinicaltrials.gov/study/NCT04566653